Smith & Nephew SNATS, Inc. $SNN Shares Acquired by River Road Asset Management LLC

River Road Asset Management LLC lifted its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 13.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,169,644 shares of the medical equipment provider’s stock after purchasing an additional 384,926 shares during the quarter. Smith & Nephew SNATS comprises approximately 1.1% of River Road Asset Management LLC’s investment portfolio, making the stock its 29th biggest position. River Road Asset Management LLC’s holdings in Smith & Nephew SNATS were worth $103,996,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Royal Bank of Canada raised its holdings in Smith & Nephew SNATS by 16.7% in the 1st quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock valued at $9,657,000 after buying an additional 48,784 shares during the period. Goldman Sachs Group Inc. boosted its stake in Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares during the period. Focus Partners Wealth boosted its stake in Smith & Nephew SNATS by 59.8% during the first quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock worth $552,000 after buying an additional 7,277 shares during the period. Cetera Investment Advisers increased its position in shares of Smith & Nephew SNATS by 5.9% during the second quarter. Cetera Investment Advisers now owns 17,731 shares of the medical equipment provider’s stock valued at $543,000 after acquiring an additional 983 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Smith & Nephew SNATS by 219.2% during the second quarter. EverSource Wealth Advisors LLC now owns 5,261 shares of the medical equipment provider’s stock valued at $161,000 after acquiring an additional 3,613 shares during the last quarter. 25.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SNN has been the topic of a number of research analyst reports. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Weiss Ratings downgraded shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Kepler Capital Markets cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock opened at $30.11 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. The business has a 50-day moving average of $31.15 and a 200 day moving average of $32.75. Smith & Nephew SNATS, Inc. has a 12 month low of $28.78 and a 12 month high of $38.79.

Smith & Nephew SNATS (NYSE:SNN) last issued its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The business had revenue of $1.60 billion for the quarter. Equities analysts anticipate that Smith & Nephew SNATS, Inc. will post 2.22 earnings per share for the current fiscal year.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.